Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK crossover study of QVM149 in Japanese and Caucasian healthy male subjects
jRCT2031200227Phase 1Completed
- Sponsor
- Novartis
- Start
- Jul 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in asthma (2 arms), sponsored by Novartis. Primary endpoint: Pharmacokinetics of indacaterol acetate, glycopyrronium bromide and mometasone furoate. Started Jul 2017; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoate
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2031200227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200227.